EP0861079A1 - Combination therapy for treating glaucoma - Google Patents
Combination therapy for treating glaucomaInfo
- Publication number
- EP0861079A1 EP0861079A1 EP96933142A EP96933142A EP0861079A1 EP 0861079 A1 EP0861079 A1 EP 0861079A1 EP 96933142 A EP96933142 A EP 96933142A EP 96933142 A EP96933142 A EP 96933142A EP 0861079 A1 EP0861079 A1 EP 0861079A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- carbon atoms
- hydrogen atom
- glaucoma
- iop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present invention relates generally to the field of ophthalmology.
- the invention relates to the treatment of glaucoma using a combination of a polyamine antagonist to preserve visual field and an intraocular pressure lowering compound.
- IOP intraocular pressure
- glaucoma has historically been treated by medically and /or surgically lowering elevated IOP, for example, by the administration of IOP-lowering agents such as motics, sympathomimetics, beta-blockers, and carbonic anhydrase inhibitors.
- IOP-lowering agents such as motics, sympathomimetics, beta-blockers, and carbonic anhydrase inhibitors.
- factors other than IOP may play a role in the occurrence of visual field loss.
- Degeneration of retinal ganglion cells may be related to ischemia or mechanical distortion ofthe nerve fibers as they exit through the optic nerve head or from pathological perturbations ofthe retina.
- excitotoxicity is neuronal injury due to excessive excitatory amino acid (“EAA") stimulation.
- EAA excitatory amino acid
- glutamate is the major EAA that permits the bipolar -ind amacrine cells to communicate with the ganglion cell.
- excitotoxicity results from hypoxia, ischemia, hypoglycemia or trauma.
- Toxicity to the inner retina has been observed following intravitreal injection of EAAs following application of EAAs to the isolated animal retina or from exogenously applied glutamate to retinal ganglion cells in culture. See generally, Sattayasai, et al., "Morphology of quisqualate-induced neurotoxicity in the chicken retina,” Invest. Ophthalmol. Vis. Sci..
- EAA receptors have been characterized as metabotropic or ionotropic. Activation of a metabotropic receptor affects cellular processes via G-proteins; whereas ionotropic receptors affect the translocation of mono- and divalent cations across the cell membrane. There are at least three ionotropic receptors that have been named for the agonist that preferentially stimulates the receptor. These receptors have been classified as: N-methyl-D-aspartate
- EAA receptors are differentially distributed to specific cells in the retina.
- Cell types using glutamate as a neurotransmitter in the vertebrate retina N.N. Osborne and G.J. Chader (Eds.) Progress in Retinal Research. Ch. 9, Pergammon Press: Oxford, 399-425 ( 1990); and Miller et al., "Excitatory amino acid receptors in the vertebrate retina,” in Retinal Transmitters and Modulators: Models for the Brain. (W.W.
- antagonists ofthe NMDA receptor are neuroprotective; however, not all antagonists of the diversely distributed EAA receptors are neuroprotective to the inner retina through antagonism of the NMDA receptor, Zeevalk et al., "Action of the anti-ischemic agent ifenprodil on N-methyl-D-aspartate and kainate-mediated excitotoxicity,"
- the present invention is directed to the use of a polyamine antagonist and an IOP controlling agent, dosed separately or in combination for the treatment of persons suffering from glaucoma or ocular hypertension.
- the present invention involves the use of two types of agents to treat glaucoma and ocular hypertension.
- One agent is an IOP-lowering agent directed at preventing the damage to retinal ganglion cells brought on by mechanical, circulatory, and other poorly understood factors related to elevated IOP.
- the second agent is a polyamine antagonist used to prevent further damage to ganglion cells and optic nerve fibers from excitotoxicity.
- Eliprodil and other polyamine antagonists are one of four classes of NMDA antagonists.
- the classes include the competitive antagonists which antagonize the glutamate recognition site, non-competitive channel blockers; glycine antagonists and polyamine antagonists, the latter two modulate the glutamate response on the receptor.
- the glycine and polyamine modulatory sites are distinct.
- antagonists of EAA receptors have been used in the CNS to prevent neuronal injury in animal models of ischemia, hypoglycemia and trauma.
- polyamine antagonists are certain l-phenyl-2-piperidinoalkanol derivatives of formula (I), below:
- R j represents a hydrogen atom, a halogen atom, a trifiuoromethyl group, an alkyl group having from 1 to 4 carbon atoms, a hydroxyl group, an alkoxy group having from 1 to
- R j may also represent a hydroxymethyl group, a carbamoyl group or an alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy part
- R2 represents a hydrogen atom, a halogen atom, an alkyl group having from 1 to 4 carbon atoms, a hydroxyl group or an alkoxy group having from 1 to 4 carbon atoms
- R3 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms
- R4 represents an alkyl group having from 1 to 4 carbon atoms, in which case the compounds are in the ( ⁇ )-erythro form, or, when R3 represents a hydrogen atom, R4 may also represent a hydrogen atom
- R j may also represent a hydroxymethyl group, a carbamoyl group or an alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy part
- R2 represents a hydrogen atom, a halogen atom, an alkyl group
- the most preferred compounds are: 2-[4-(4-fluorobenzyl)-piperidino]-l-(4- chlorophenyl)-ethanol, also known as eliprodil; 2-(4-benzylpiperidino)-l -(4-hydroxyphenyl)- propanol, also known as ifenprodil; or a pharmaceutically acceptable salt thereof.
- eliprodil 2-[4-(4-fluorobenzyl)-piperidino]-l-(4- chlorophenyl)-ethanol
- ifenprodil 2-(4-benzylpiperidino)-l -(4-hydroxyphenyl)- propanol
- ifenprodil 2-(4-benzylpiperidino)-l -(4-hydroxyphenyl)- propanol
- ifenprodil 2-(4-benzylpiperidino)-l -(4-hydroxyphenyl)- propanol
- the polyamine antagonists useful in the present invention will be administered orally.
- Daily dosage of these compounds will range between about 0.1 and about 500 milligrams (mg), preferably between about 5 and about 100 mg. While at the present time there are no effective methods for local administration to the back of the eye for chronic indications, it is contemplated that such methods will be developed. If local chronic administration of these compounds becomes feasible, it is expected that the dosage will range between about 0.1 and about 500 mg, preferably between about 5 and about 100 mg.
- An aqueous composition will generally contain between about 0.1 and about 10 percent by weight (wt%) ofthe active, preferably between about 1 and about 5 wt%.
- the IOP-lowering agents useful in the present invention include all presently known IOP-lowering pharmaceuticals, including miotics (e.g., pilocarpine, carbachol and acetylcholinesterase inhibitors); sympathomimetics (e.g., epinephrine, dipivalylepinephrine and para-amino clonidine); beta-blockers (e.g., betaxolol, levobunolol, cartelol, and timolol); prostaglandins and their analogues and derivatives (e.g., F series (such as PGF2 ), E series
- miotics e.g., pilocarpine, carbachol and acetylcholinesterase inhibitors
- sympathomimetics e.g., epinephrine, dipivalylepinephrine and para-amino clonidine
- beta-blockers e.g., betaxolol
- the preferred IOP-lowering agents are: timolol, betaxolol, levobunolol, carteolol, pilocarpine, carbachol, epinephrine, dipivalyl epinephrine, -methyl dipivalylepinephrine, dorzolamide, latanoprost, apraclonidine, and clonidine.
- the IOP-lowering agent will be administered in a topical formulation at a concentration of between 0.001 and 5.0 wt%, preferably, 0.01 to 2.5 wt%.
- the IOP-lowering compositions ofthe present invention may additionally include components to provide sustained release and/or comfort.
- Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Patent Nos.
- the IOP-lowering compositions of the present invention may further comprise various formulatory ingredients, such as antimicrobial preservatives and tonicity agents.
- antimicrobial preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M® and other agents equally well-known to those skilled in the art.
- Such preservatives, if utilized, will typically be employed in an amount between about 0.001 and about 1.0 wt%.
- compositions may be formulated in various dosage forms suitable for topical ophthalmic delivery, including solutions, suspensions, emulsions, gels, and erodible solid ocular inserts.
- the compositions are preferably aqueous suspensions or solutions.
- compositions ofthe present invention may also comprise non-aqueous formulations such as: substantially non-aqueous liquids substantially non-aqueous semi-solid compositions and solid compositions or devices.
- the first class, substantially non-aqueous liquids comprise an IOP-lowering agent and a second agent ("drug combination") dissolved or suspended in one or more of the following: vegetable and mineral oils, such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil; triglycerides, such as the capric/caprylic triglycerides commonly used in foods and cosmetics; liquid lanolin and lanolin derivatives; and perfluorohydrocarbons.
- vegetable and mineral oils such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil
- triglycerides such as the capric/caprylic triglycerides commonly used in foods and cosmetics
- liquid lanolin and lanolin derivatives such as the capric/caprylic triglycerides commonly used in foods and cosmetics
- perfluorohydrocarbons such as the capric/caprylic triglycerides commonly used in foods and cosmetics.
- the second class, semi-solid compositions comprise an IOP-lowering agent dissolved or suspended in one or more ofthe following: various types of petrolatum, such as white, yellow, red and so on; lanolin and lanolin derivatives; gelled mineral oil having a hydrocarbon base, such as Plastibase®; petrolatum and ethylene carbonate mixtures; petrolatum in combination with surfactants and polyglycol, such as polyoxyl 40 stearate and polyethylene glycol.
- various types of petrolatum such as white, yellow, red and so on
- lanolin and lanolin derivatives such as gelled mineral oil having a hydrocarbon base, such as Plastibase®
- petrolatum and ethylene carbonate mixtures such as polyoxyl 40 stearate and polyethylene glycol.
- the third class, solid compositions or devices include non-erodible devices which are inserted into the conjunctival sac ofthe eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctival sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on).
- non-erodible devices which are inserted into the conjunctival sac ofthe eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctival sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on).
- bioerodible inserts described and detailed in US 4,540,408 (Lloyd) and US 4,730,013 (Bondi et al.), wherein drug combinations of the present invention would be entrained in a non-aqueous matrix consisting essentially of polyvinyl alcohol.
- US 4,540,408 Lioyd
- US 4,730,013 Nondi et al.
- the present invention is also directed to methods of treating persons with glaucoma or ocular hypertension.
- the polyamine antagonist will be administered systemically and the IOP-lowering compositions described above are applied topically to the affected eye(s) of the patient.
- the frequency and amount of dosage will be determined by the clinician based on various clinical factors.
- the methods will typically comprise topical application of one or two drops (or an equivalent amount of a solid or semi-solid dosage form) to the affected eye one to four times per day.
- the preferred method for treatment is administering eliprodil and betaxolol or timolol.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Methods for treating persons with glaucoma or ocular hypertension with polyamine antagonists and an IOP-lowering compounds are also disclosed.
Description
COMBINATION THERAPY FOR TREATING GLAUCOMA
The present invention relates generally to the field of ophthalmology. In particular, the invention relates to the treatment of glaucoma using a combination of a polyamine antagonist to preserve visual field and an intraocular pressure lowering compound.
Background of the Invention
Although the underlying causes of glaucoma are not understood at this time, glaucoma is characterized by damage to the optic nerve, accompanied by a decrease in the normal visual field. One early warning sign of possible glaucomatous visual field loss is elevated intraocular pressure ("IOP"). In fact, glaucoma has historically been treated by medically and /or surgically lowering elevated IOP, for example, by the administration of IOP-lowering agents such as motics, sympathomimetics, beta-blockers, and carbonic anhydrase inhibitors. However, factors other than IOP may play a role in the occurrence of visual field loss. Degeneration of retinal ganglion cells may be related to ischemia or mechanical distortion ofthe nerve fibers as they exit through the optic nerve head or from pathological perturbations ofthe retina.
There has been a growing interest in retinal dysfunction as a contributor to the glaucomatous process. Retinal dysfunction, and hence pathology, may be related to ischemia
or excitotoxicity. Excitotoxicity is neuronal injury due to excessive excitatory amino acid ("EAA") stimulation. In the inner retina, glutamate is the major EAA that permits the bipolar -ind amacrine cells to communicate with the ganglion cell. In the central nervous system, excitotoxicity results from hypoxia, ischemia, hypoglycemia or trauma. (See, for example, Beal, M.F., "Mechanisms of excitotoxicity in neurologic diseases," FASEB J.. 6:3338-3344
(1992); and Choi, D.W., "Excitotoxic cell death," J. Neurobiol.. 23: 1261-1276 (1992).) Toxicity to the inner retina has been observed following intravitreal injection of EAAs following application of EAAs to the isolated animal retina or from exogenously applied glutamate to retinal ganglion cells in culture. See generally, Sattayasai, et al., "Morphology of quisqualate-induced neurotoxicity in the chicken retina," Invest. Ophthalmol. Vis. Sci..
28: 106-1 17 (1987); Tung et al., "A quantitative analysis of the effects of excitatory neurotoxins on retinal ganglion cells in the chick, Visual Neurosci.. 4:217-223 (1990); Sisk et al., "Histological changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamate," Graefe's Arch. Clin. Exp. Ophthalmol.. 223:250-258 (1985); Siliprandi et al., "N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina," Visual
Neurosci .. 8:567-573 (1992); Reif-Lehrer et al., "Effects of monosodium glutamate on chick embryo retina in culture," Invest. Ophthalmol. Vis. Sci.. 14(2): 1 14-124 (1975); Blanks, J. C, "Effects of monosodium glutamate on the isolated retina of the chick embryo as a function of age: A morphological study," Exp. Eve Res.. 32: 105-124 (1981); Olney et al., "The role of specific ions in glutamate neurotoxicity," Neurosci. Lett.. 65:65-71 (1986); Olney et al., "The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics," Neurosci. Lett 68:29-34 (1986); Price et al., "CNQX potently and selectively blocks kainate excitotoxicity in the chick embryo retina," Soc. Neurosci. Abst.. 14:418 (1988); David et al., "Involvement of excitatory neurotransmitters in the damage produced in chick embryo retinas by anoxia and extracellular high potassium," Exp. Eye Res.. 46:657-662 ( 1988); Caprioli et al., "Large retinal ganglion cells are more susceptible to excitotoxic and hypoxic injury than small cells Invest. Ophthalmol. Vis. Sci.. 34(Suppl): 1429 (1993); Cummins et al, "Electrophysiology of cultured retinal ganglion cells to investigate basic mechanics of damage," Glaucoma Update IV. 59-65 (1991); and Sucher et al., "N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro," J. Neurosci..
11(4):966-971 (1991).
EAA receptors have been characterized as metabotropic or ionotropic. Activation of a metabotropic receptor affects cellular processes via G-proteins; whereas ionotropic receptors affect the translocation of mono- and divalent cations across the cell membrane. There are at least three ionotropic receptors that have been named for the agonist that preferentially stimulates the receptor. These receptors have been classified as: N-methyl-D-aspartate
-?-
(NMDA); kainate; and AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid). These EAA receptors are differentially distributed to specific cells in the retina. (See, for example, Massey, S., "Cell types using glutamate as a neurotransmitter in the vertebrate retina," N.N. Osborne and G.J. Chader (Eds.) Progress in Retinal Research. Ch. 9, Pergammon Press: Oxford, 399-425 ( 1990); and Miller et al., "Excitatory amino acid receptors in the vertebrate retina," in Retinal Transmitters and Modulators: Models for the Brain. (W.W. Morgan, Ed.) CRC Press, Inc., Boca Raton, 11: 123-160 (1985).) The localization of such receptors would account for the pathologies associated with glaucoma or inner retinal ischemia. For example, death ofthe retinal ganglion cell has to a large part been attributed to the NMDA receptor. (See, for example, Sucher et al., "N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in retinal ganglion cells in vitro," J. Neurosci.. 11(4):966-971 (1991).). Thus, antagonists ofthe NMDA receptor are neuroprotective; however, not all antagonists of the diversely distributed EAA receptors are neuroprotective to the inner retina through antagonism of the NMDA receptor, Zeevalk et al., "Action of the anti-ischemic agent ifenprodil on N-methyl-D-aspartate and kainate-mediated excitotoxicity,"
Brain Res.. 522: 135-139 (1990)), and many of these EAA antagonists have significant CNS side-effects and are therefore not suitable for treating these degenerative diseases of the eye.
Summary of the Invention
The present invention is directed to the use of a polyamine antagonist and an IOP controlling agent, dosed separately or in combination for the treatment of persons suffering from glaucoma or ocular hypertension.
Detailed Description of the Invention
The present invention involves the use of two types of agents to treat glaucoma and ocular hypertension. One agent is an IOP-lowering agent directed at preventing the damage to retinal ganglion cells brought on by mechanical, circulatory, and other poorly understood factors related to elevated IOP. The second agent is a polyamine antagonist used to prevent further damage to ganglion cells and optic nerve fibers from excitotoxicity.
Eliprodil and other polyamine antagonists are one of four classes of NMDA antagonists. (See, for example, Ornstein et al., "Antagonists of the NMDA receptor complex," DN&P. 7(1):5-12 (1994).) The classes include the competitive antagonists which
antagonize the glutamate recognition site, non-competitive channel blockers; glycine antagonists and polyamine antagonists, the latter two modulate the glutamate response on the receptor. The glycine and polyamine modulatory sites are distinct. As aforementioned, antagonists of EAA receptors have been used in the CNS to prevent neuronal injury in animal models of ischemia, hypoglycemia and trauma. Pharmacologically, competitive and non¬ competitive antagonists suffer from their inability to cross the blood-brain barrier or that they produce undesirable (psychotomimetic) side effects. Unlike other NMDA antagonists, the polyamine antagonists such as eliprodil partition across the blood-brain barrier and produce their actions at a modulatory site without side-effects typical of non-competitive antagonists. (See, for example, Lipton, S.A., "Prospects for clinically tolerated NMDA antagonists: open- channel blockers and alternative redox states of nitric oxide," TINS. 16(12): 527-532 (1993).)
Particularly preferred polyamine antagonists are certain l-phenyl-2-piperidinoalkanol derivatives of formula (I), below:
OH r
X-
^ R4
(I) wherein:
Rj represents a hydrogen atom, a halogen atom, a trifiuoromethyl group, an alkyl group having from 1 to 4 carbon atoms, a hydroxyl group, an alkoxy group having from 1 to
4 carbon atoms, a benzyloxy group, an alkanoyloxy group having from 1 to 16 carbon atoms or a benzoyloxy group, or, when R2 represents a hydroxyl or methoxy group in the 4-position and R3 represents a hydrogen atom, Rj may also represent a hydroxymethyl group, a carbamoyl group or an alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy part, R2 represents a hydrogen atom, a halogen atom, an alkyl group having from 1 to 4 carbon atoms, a hydroxyl group or an alkoxy group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, R4 represents an alkyl group having from 1 to 4 carbon atoms, in which case the compounds are in the (±)-erythro form, or, when R3 represents a hydrogen atom, R4 may also represent a hydrogen atom, and R5 represents a hydrogen atom, a halogen atom, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4
-A-
carbon atoms or a set of three methoxy groups in the 3-, 4- and 5-positions ofthe benzyl radical, and pharmaceutically acceptable acid addition salts thereof.
The compounds of formula (I) above are described in US 4,690,931 (Wick et al.); however, there is no mention in that patent of ophthalmic indications for such compounds. Wick et al. also describe methods for synthesizing such compounds. The entire contents of US 4,690,931 are incorporated herein by reference.
The most preferred compounds are: 2-[4-(4-fluorobenzyl)-piperidino]-l-(4- chlorophenyl)-ethanol, also known as eliprodil; 2-(4-benzylpiperidino)-l -(4-hydroxyphenyl)- propanol, also known as ifenprodil; or a pharmaceutically acceptable salt thereof. The structures of eliprodil and ifenprodil are shown below.
Cl "
Eliprodil
OH
N
CH3
HO
Ifenprodil
In general, the polyamine antagonists useful in the present invention will be administered orally. Daily dosage of these compounds will range between about 0.1 and about 500 milligrams (mg), preferably between about 5 and about 100 mg. While at the present time there are no effective methods for local administration to the back of the eye for chronic indications, it is contemplated that such methods will be developed. If local chronic
administration of these compounds becomes feasible, it is expected that the dosage will range between about 0.1 and about 500 mg, preferably between about 5 and about 100 mg. An aqueous composition will generally contain between about 0.1 and about 10 percent by weight (wt%) ofthe active, preferably between about 1 and about 5 wt%.
The IOP-lowering agents useful in the present invention, include all presently known IOP-lowering pharmaceuticals, including miotics (e.g., pilocarpine, carbachol and acetylcholinesterase inhibitors); sympathomimetics (e.g., epinephrine, dipivalylepinephrine and para-amino clonidine); beta-blockers (e.g., betaxolol, levobunolol, cartelol, and timolol); prostaglandins and their analogues and derivatives (e.g., F series (such as PGF2 ), E series
(such as PGE2), D series (such as PGD2) and compounds disclosed in U.S. Patent Nos. 4,599,353; 5,093,329; and 5,321,128, and in European Patent Nos. 0215 860 Bl and 0 299 914 Bl ; and carbonic anhydrase inhibitors (e.g., acetazolamide, methazolamide, and ethoxzolamide, and compounds disclosed in U.S. Patent Nos. 5,153,192; 5,240,923; 5,378,703; and 4,797,413). The preferred IOP-lowering agents are: timolol, betaxolol, levobunolol, carteolol, pilocarpine, carbachol, epinephrine, dipivalyl epinephrine, -methyl dipivalylepinephrine, dorzolamide, latanoprost, apraclonidine, and clonidine.
The IOP-lowering agent will be administered in a topical formulation at a concentration of between 0.001 and 5.0 wt%, preferably, 0.01 to 2.5 wt%.
The IOP-lowering compositions ofthe present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Patent Nos.
4,911 ,920; 5,403,841 ; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference.
In addition to the above-described principal ingredients, the IOP-lowering compositions of the present invention may further comprise various formulatory ingredients, such as antimicrobial preservatives and tonicity agents. Examples of suitable antimicrobial preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M® and other agents equally well-known to those skilled in the art. Such preservatives, if utilized, will typically be employed in an amount between about 0.001 and about 1.0 wt%. Examples of suitable agents which may be used to adjust the tonicity or osmolality ofthe formulations include: sodium chloride, potassium chloride, mannitol, dextrose, glycerin, and propylene
glycol. Such agents, if utilized, will typically be employed in an amount between about 0.1 and about 10.0 wt%.
As will be appreciated by those skilled in the art, the compositions may be formulated in various dosage forms suitable for topical ophthalmic delivery, including solutions, suspensions, emulsions, gels, and erodible solid ocular inserts. The compositions are preferably aqueous suspensions or solutions.
The compositions ofthe present invention may also comprise non-aqueous formulations such as: substantially non-aqueous liquids substantially non-aqueous semi-solid compositions and solid compositions or devices.
The first class, substantially non-aqueous liquids, comprise an IOP-lowering agent and a second agent ("drug combination") dissolved or suspended in one or more of the following: vegetable and mineral oils, such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil; triglycerides, such as the capric/caprylic triglycerides commonly used in foods and cosmetics; liquid lanolin and lanolin derivatives; and perfluorohydrocarbons.
The second class, semi-solid compositions, comprise an IOP-lowering agent dissolved or suspended in one or more ofthe following: various types of petrolatum, such as white, yellow, red and so on; lanolin and lanolin derivatives; gelled mineral oil having a hydrocarbon base, such as Plastibase®; petrolatum and ethylene carbonate mixtures; petrolatum in combination with surfactants and polyglycol, such as polyoxyl 40 stearate and polyethylene glycol.
The third class, solid compositions or devices, include non-erodible devices which are inserted into the conjunctival sac ofthe eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctival sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on).
Especially preferred are the bioerodible inserts described and detailed in US 4,540,408 (Lloyd) and US 4,730,013 (Bondi et al.), wherein drug combinations of the present invention would be entrained in a non-aqueous matrix consisting essentially of polyvinyl alcohol. The entire contents of these two patents are incorporated herein by reference.
The present invention is also directed to methods of treating persons with glaucoma or ocular hypertension. The polyamine antagonist will be administered systemically and the
IOP-lowering compositions described above are applied topically to the affected eye(s) of the patient. The frequency and amount of dosage will be determined by the clinician based on various clinical factors. The methods will typically comprise topical application of one or two drops (or an equivalent amount of a solid or semi-solid dosage form) to the affected eye one to four times per day. The preferred method for treatment is administering eliprodil and betaxolol or timolol.
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope ofthe invention being indicated by the appended claims rather than by the foregoing description.
Claims
1. A method for treating a person suffering from glaucoma or ocular hypertension which comprises, administering a polyamine antagonist and an intraocular pressure lowering agent.
2. The method of Claim 1 wherein the polyamine antagonist has the structure:
OH
R, H i 1
>χ- -' N »
R2
R3
(I) wherein: Rj represents a hydrogen atom, a halogen atom, a trifiuoromethyl group, an alkyl group having from 1 to 4 carbon atoms, a hydroxyl group, an alkoxy group having from 1 to 4 carbon atoms, a benzyloxy group, an alkanoyloxy group having from 1 to 16 carbon atoms or a benzoyloxy group, or, when R2 represents a hydroxyl or methoxy group in the 4-position and R3 represents a hydrogen atom, Rj may also represent a hydroxymethyl group, a carbamoyl group or an alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy part, R2 represents a hydrogen atom, a halogen atom, an alkyl group having from 1 to 4 carbon atoms, a hydroxyl group or an alkoxy group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, R4 represents an alkyl group having from 1 to 4 carbon atoms, in which case the compounds are in the (±)-erythro form, or, when R3 represents a hydrogen atom, R4 may also represent a hydrogen atom, and R5 represents a hydrogen atom, a halogen atom, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms or a set of three methoxy groups in the 3-, 4- and 5 -positions of the benzyl radical, and pharmaceutically acceptable acid addition salts thereof.
3. The method of Claim 1 wherein the IOP-lowering agent is selected from the group consisting of miotics, sympathomimetics, beta-blockers, prostaglandins, and carbonic anhydrase inhibitors.
4. The method of Claim 2 wherein the polyamine antagonist is eliprodil.
5. The method of Claim 3 wherein the IOP-lowering agent is betaxolol.
6. A method for treating a person suffering from glaucoma or ocular hypertension which comprises, administering eliprodil and betaxolol.
7. A method for treating a person suffering from glaucoma or ocular hypertension which comprises, administering eliprodil and timolol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00201636A EP1057486A1 (en) | 1995-11-17 | 1996-09-26 | Use of drug combination for treating Glaucoma |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56005595A | 1995-11-17 | 1995-11-17 | |
US560055 | 1995-11-17 | ||
PCT/US1996/015410 WO1997018812A1 (en) | 1995-11-17 | 1996-09-26 | Combination therapy for treating glaucoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00201636A Division EP1057486A1 (en) | 1995-11-17 | 1996-09-26 | Use of drug combination for treating Glaucoma |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0861079A1 true EP0861079A1 (en) | 1998-09-02 |
Family
ID=24236158
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00201636A Withdrawn EP1057486A1 (en) | 1995-11-17 | 1996-09-26 | Use of drug combination for treating Glaucoma |
EP96933142A Withdrawn EP0861079A1 (en) | 1995-11-17 | 1996-09-26 | Combination therapy for treating glaucoma |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00201636A Withdrawn EP1057486A1 (en) | 1995-11-17 | 1996-09-26 | Use of drug combination for treating Glaucoma |
Country Status (5)
Country | Link |
---|---|
US (1) | US5883108A (en) |
EP (2) | EP1057486A1 (en) |
AU (1) | AU704938B2 (en) |
CA (1) | CA2237898A1 (en) |
WO (1) | WO1997018812A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335335B2 (en) * | 1997-11-05 | 2002-01-01 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
EP1169061A1 (en) * | 1999-03-12 | 2002-01-09 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
PT1221917E (en) * | 1999-10-21 | 2005-04-29 | Alcon Inc | DEVICE FOR MINISTRY OF MEDICINES |
AU2001261360A1 (en) * | 2000-05-10 | 2001-11-20 | Alcon, Inc. | R-eliprodil for treating glaucoma |
US20030212107A1 (en) * | 2001-05-10 | 2003-11-13 | Kapin Michael A. | R-reliprodil for treating glaucoma |
TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
US7030149B2 (en) | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
EP1858501A1 (en) * | 2005-03-07 | 2007-11-28 | Michael Hermanussen | Nmda receptor antagonists in the medical intervention of metabolic disorders |
GB2432526A (en) * | 2005-11-24 | 2007-05-30 | Arakis Ltd | Use of ifenprodil for the treatment of ophthalmic diseases |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
AU2011282681B2 (en) | 2010-07-29 | 2015-07-30 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ200429A (en) * | 1981-04-30 | 1984-10-19 | Smith & Nephew Ass | Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye |
US4730013A (en) * | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
FR2534580A1 (en) * | 1982-10-13 | 1984-04-20 | Synthelabo | PHENYL-1 PIPERIDINO-2 PROPANOL DERIVATIVES, THEIR PREPARATION, AND MEDICINES THAT CONTAIN THEM |
US4911920A (en) * | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US4797413A (en) * | 1986-05-14 | 1989-01-10 | Merck & Co., Inc. | Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use |
DE3510978A1 (en) * | 1985-03-22 | 1986-09-25 | Schering AG, Berlin und Bergkamen, 1000 Berlin | NEW 9-HALOGEN PROSTAGLANDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
FR2588189B1 (en) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
ES2054860T5 (en) * | 1987-07-17 | 2003-11-01 | Schering Ag | DERIVATIVES OF 9-HALOGEN- (Z) -PROSTAGLANDINAS, PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS. |
JP2610619B2 (en) * | 1987-07-22 | 1997-05-14 | エーザイ株式会社 | Eye drops for the treatment of ocular hypertension |
US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
JP2824863B2 (en) * | 1989-07-12 | 1998-11-18 | エーザイ株式会社 | α ▲ Lower 1 ▼ -Blocker eye drops |
US5093329A (en) * | 1990-03-12 | 1992-03-03 | Allergan, Inc. | Intraocular pressure reducing prostaglandin-like 7-oxabicyclo derivatives |
US5153192A (en) * | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
US5378703A (en) * | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
DE69212850T2 (en) * | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Use of carrageenan in topical ophthalmic compositions |
US5212162A (en) * | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
US5710165A (en) * | 1994-07-06 | 1998-01-20 | Synthelabo | Use of polyamine antagonists for the treatment of glaucoma |
JPH08231400A (en) * | 1995-02-24 | 1996-09-10 | Rohto Pharmaceut Co Ltd | Intraocular pressure-lowering agent containing ifenprodil as essential ingredient |
-
1996
- 1996-09-26 AU AU71683/96A patent/AU704938B2/en not_active Ceased
- 1996-09-26 EP EP00201636A patent/EP1057486A1/en not_active Withdrawn
- 1996-09-26 EP EP96933142A patent/EP0861079A1/en not_active Withdrawn
- 1996-09-26 CA CA002237898A patent/CA2237898A1/en not_active Abandoned
- 1996-09-26 WO PCT/US1996/015410 patent/WO1997018812A1/en not_active Application Discontinuation
-
1997
- 1997-08-28 US US08/919,882 patent/US5883108A/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO9718812A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU7168396A (en) | 1997-06-11 |
AU704938B2 (en) | 1999-05-06 |
US5883108A (en) | 1999-03-16 |
EP1057486A1 (en) | 2000-12-06 |
WO1997018812A1 (en) | 1997-05-29 |
CA2237898A1 (en) | 1997-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6441047B2 (en) | Combination therapy for treating glaucoma | |
EP0868186B1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
US5710165A (en) | Use of polyamine antagonists for the treatment of glaucoma | |
JP2732312B2 (en) | Anti-glaucoma composition comprising a combination of an alpha-2 agonist and a beta blocker | |
US5883108A (en) | Combination therapy for treating glaucoma | |
EP1169061A1 (en) | Combination therapy for treating glaucoma | |
EP1568382B1 (en) | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER | |
US6172054B1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
US5106855A (en) | Method for the treatment of glaucoma | |
US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
WO1997024123A1 (en) | Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye | |
AU2001217709B2 (en) | Combination therapy for lowering and controlling intraocular pressure | |
US5308849A (en) | Method of reducing elevated intraocular pressure | |
EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
AU2001217709A1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
AU716577B2 (en) | Use of polyamine antagonists for the treatment of glaucoma | |
AU2004214563A1 (en) | Combination therapy for treating glaucoma | |
EP0277814B1 (en) | Anti-glaucoma use of trifluoromethanesulfonamide | |
AU2006200143B2 (en) | Combination therapy for lowering and controlling intraocular pressure | |
IE904607A1 (en) | Method for the treatment of glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980608 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20001213 |